文献速递其他结缔组织病

硬皮病以患者为中心的干预网络(SPIN)队列中的疼痛水平及相关因素:一项多中心横断面研究

Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study.
PubMed 文献 · Lancet Rheumatol · 2021-01-01

该多中心横断面研究纳入SPIN队列中2014年4月15日至2020年1月7日来自46个中心的2157例系统性硬化症患者,评估疼痛强度与干扰水平及其相关因素。1870例(87%)报告轻度至重度疼痛,815例(38%)报告中度至重度疼痛,757例(35%)报告中度至重度疼痛干扰。控制社会人口学变量后,疼痛强度与女性、非白人种族、受教育年限少、加拿大和英国(对照美国)、较高体重指数、关节挛缩、指端溃疡、胃肠道受累、皮肤受累、类风湿关节炎及干燥综合征独立相关,疼痛干扰结果相似。

要点

  • 2157例系统性硬化症患者中1870例(87%)报告轻度至重度疼痛(0-10分≥1分)。
  • 815例(38%)报告中度至重度疼痛(≥5分),757例(35%)报告中度至重度疼痛干扰。
  • 控制社会人口学变量后,关节挛缩、指端溃疡、胃肠道受累、皮肤受累及重叠综合征与更高疼痛独立相关。

核心结论

  • 疼痛在系统性硬化症患者中常见,控制社会人口学变量后,更高疼痛与多种系统性硬化症相关表现相关,包括关节挛缩、指端溃疡、胃肠道受累、皮肤受累及重叠综合征的存在。
  • 医疗保健提供者应与患者合作处理疼痛,包括识别和处理与疼痛相关的系统性硬化症表现,并支持行为干预以尽量减少对功能和生活质量的影响。

研究设计与样本

  • 多中心横断面研究,纳入SPIN队列中完成疼痛强度和干扰测量(PROMIS-29 profile version 2·0)的基线评估参与者。
  • 患者于2014年4月15日至2020年1月7日从澳大利亚、加拿大、法国、墨西哥、西班牙、英国和美国的46个中心招募。
  • 纳入标准为年龄18岁及以上且符合美国风湿病学会和欧洲抗风湿病联盟制定的系统性硬化症分类标准。
  • 采用多重线性回归评估疼痛强度和疼痛干扰与系统性硬化症相关变量及重叠综合征的关联,并控制社会人口学变量;连续自变量经标准化处理。

主要发现

  • 2157例参与者中男性268例(12%)、女性1889例(88%);1870例(87%)报告轻度、中度或重度疼痛(0-10分量表≥1分),815例(38%)报告中度或重度疼痛(≥5分),757例(35%)报告中度或重度疼痛干扰。
  • 更高疼痛强度独立相关因素包括:女性(0·58分,95%CI 0·26-0·90)、非白人种族或族裔(0·50分,95%CI 0·21-0·79)、受教育年限较少(每标准差0·30分,95%CI 0·19-0·41)、国家(对照美国;加拿大0·29分,95%CI 0·01-0·57;英国0·58分,95%CI 0·21-0·95)、较高体重指数(每标准差0·35分,95%CI 0·24-0·45)。
  • 更高疼痛强度独立相关因素还包括:关节挛缩(0·67分,95%CI 0·39-0·94)、指端溃疡(0·33分,95%CI 0·10-0·55)、胃肠道受累(0·66分,95%CI 0·33-0·98)、皮肤受累(采用改良Rodnan皮肤评分,每标准差0·22分,95%CI 0·10-0·35)、类风湿关节炎(0·96分,95%CI 0·50-1·43)及干燥综合征(0·42分,95%CI 0·01-0·83)。
  • 疼痛干扰结果与疼痛强度结果相似。

关键数值与推荐

  • 疼痛轻度至重度定义为0-10分量表≥1分,1870例(87%)符合。
  • 疼痛中度至重度定义为0-10分量表≥5分,815例(38%)符合。
  • 中度或重度疼痛干扰见于757例(35%)参与者。

临床怎么用

  • 医疗保健提供者应与患者合作处理疼痛,包括识别和处理与疼痛相关的系统性硬化症表现,并支持行为干预以尽量减少对功能和生活质量的影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pain is an important and detrimental feature of systemic sclerosis but is often overlooked or deprioritised in research and clinical care. Raynaud's phenomenon, arthritis, and cutaneous ulcers are among the commonly reported disease manifestations of systemic sclerosis that could be associated with pain. We aimed to assess levels of pain intensity and interference and to evaluate disease factors associated with pain intensity and interference. METHODS: In this multicentre cross-sectional study, participants from the Scleroderma Patient-centered Intervention Network cohort who completed pain intensity and interference measures (Patient Reported Outcomes Information System-29 profile, version 2·0) as part of baseline assessments were included. Patients were recruited from 46 centres in Australia, Canada, France, Mexico, Spain, the UK, and the USA between April 15, 2014, and Jan 7, 2020. Eligible patients included those aged 18 years or older who met the criteria for systemic sclerosis devised by the American College of Rheumatology and the European League Against Rheumatism. Associations of pain intensity and pain interference with systemic sclerosis-related variables and overlap syndromes, controlling for sociodemographic variables, were assessed with multiple linear regression. Continuous independent variables were standardised. FINDINGS: Among 2157 participants with systemic sclerosis (268 [12%] males and 1889 [88%] females), 1870 (87%) reported mild, moderate, or severe pain (defined as ≥1 on a 0 to 10 scale), and 815 (38%) reported moderate or severe pain (defined as ≥5). Moreover, 757 (35%) participants reported moderate or severe pain interference. Greater pain intensity was independently associated with female sex (0·58 points [95% CI 0·26-0·90]), non-White race or ethnicity (0·50 points [0·21-0·79]), fewer years in formal education (0·30 points per SD [0·19-0·41]), country (reference: USA; Canada: 0·29 points [0·01-0·57] and UK: 0·58 points [0·21-0·95]), greater body-mass index (0·35 points per SD [0·24-0·45]); joint contractures (0·67 points [0·39-0·94]), digital ulcers (0·33 points [0·10-0·55]), gastrointestinal involvement (0·66 points [0·33-0·98]), skin involvement (measured using modified Rodnan skin score; 0·22 points per SD [0·10-0·35]), rheumatoid arthritis (0·96 points [0·50-1·43]), and Sjögren's syndrome (0·42 points [0·01-0·83]). Pain interference results were similar. INTERPRETATION: Pain is common among people with systemic sclerosis. Controlling for sociodemographic variables, greater pain was associated with multiple systemic sclerosis-related manifestations, including joint contractures, digital ulcers, gastrointestinal involvement, skin involvement, and the presence of overlap syndromes. Health-care providers should work with patients to address pain, including identifying and addressing systemic sclerosis manifestations associated with their pain, and supporting behavioural approaches to minimise impact on function and quality of life. FUNDING: Canadian Institutes of Health Research, Arthritis Society, The Lady Davis Institute for Medical Research of the Jewish General Hospital, Jewish General Hospital Foundation, McGill University, Scleroderma Society of Ontario, Scleroderma Canada, Sclérodermie Québec, Scleroderma Manitoba, Scleroderma Atlantic, Scleroderma Association of BC, Scleroderma SASK, Scleroderma Australia, Scleroderma New South Wales, Scleroderma Victoria, and Scleroderma Queensland.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Lee YC, Fox RS, Kwakkenbos L, et al. Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. Lancet Rheumatol. 2021. PMID: 38287631. doi:10.1016/S2665-9913(21)00318-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。